Between 20, the Cluster of Excellence PhoenixD at the Leibniz University Hannover will receive approximately 52 million euros of funding from the federal government and the State of Lower Saxony via the German Research Foundation (DFG). In September 2018, the Cluster of Excellence PhoenixD, along with 56 other Clusters, was recommended by an international review panel and approved by the German Research Foundation (DFG). What is a Cluster of Excellence? Clusters of Excellence support outstanding research fields at German universities. This program is gaining popularity worldwide. The Leibniz University has been offering an international Master's program in Optical Technologies in English and German for several years. In seminars, lectures and excursions, as well as during the annual summer school, the participants supplement their interdisciplinary studies. What do we teach? For doctoral students, we founded the PhoenixD Research School (PRS). The Leibniz School is closely linked to the PhoenixD cluster of excellence and has the same structure as a faculty. Leibniz University Hannover bundled its expertise in the field of optics more firmly and has established the Leibniz School of Optics & Photonics (LSO) in spring 2020. At Leibniz University Hannover, we extend this scope to engineering sciences, chemistry and computer sciences to reflect the importance of optics in industry and society as an interdisciplinary subject. Optical technologies are usually regarded as a field of physics. Machine learning, artificial neural networks and artificial intelligence are keywords that are also becoming increasingly important for optics and photonics. Examples are lensless cameras or 3D printing in the production of optical components. In addition to classical computer simulations, the main focus is on approaches that would be unthinkable without digital technology. What are we researching? PhoenixD is exploring the possibilities of digitalization for novel optical systems as well as their production and application. Optical sensors and high-resolution cameras are a prerequisite for autonomous driving in the future, and lasers are replacing the scalpel in medical technology. Optical glass fibres are the backbone of the internet and mobile networks. Photonics is one of the key technologies of the 21st century. The team is as interdisciplinary as the research on optics and photonics itself. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.The Cluster of Excellence PhoenixD – Photonics, Optics, and Engineering – Innovation Across Disciplines In the Cluster of Excellence PhoenixD (Photonics, Optics, and Engineering – Innovation Across Disciplines) more than 100 physicists, mechanical engineers, chemists, electrical engineers, computer scientists and mathematicians work together in the field of optical technologies.
The GENE WRITING platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. Rowe Price Associates, Inc., and others including all of Tessera's existing institutional shareholders. Investors included a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA) Alaska Permanent Fund Corporation Altitude Life Science Ventures ARTIS Ventures Cormorant Asset Management Tessera's founder, Flagship Pioneering Hanwha Impact Partners Longevity Vision Fund March Capital SALT Fund SoftBank Vision Fund 2 funds and accounts advised by T.
#TESSERA THERAPEUTICS STOCKS SERIES#
Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as GENE WRITING technology, announced today that it has raised over $300 million in Series C financing.
0 kommentar(er)
